Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Página do item simplificado
dc.creatorJairo Sebastian Astudillo Vallejo
dc.creatorFábio Lopes de Queiroz
dc.creatorAntonio Lacerda Filho
dc.creatorPaulo Rocha França Neto
dc.creatorBreno Xaia m. Costa
dc.creatorRodrigo de Almeida Paiva
dc.creatorSilverio Leonardo Macedo Garcia
dc.creatorSergio Botrel Silva
dc.date.accessioned2025-08-04T18:14:32Z
dc.date.accessioned2025-09-09T00:13:12Z
dc.date.available2025-08-04T18:14:32Z
dc.date.issued2023
dc.format.mimetypepdf
dc.identifier.doi10.1590/0100-6991e-20233421
dc.identifier.issn01006991
dc.identifier.urihttps://hdl.handle.net/1843/83994
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.rightsAcesso Aberto
dc.subjectMortality
dc.subjectSurvival.
dc.subjectPeritoneal Diseases
dc.subjectCytoreduction Surgical Procedures
dc.subjectHyperthermic Intraperitoneal Chemotherapy
dc.subject.otherMortality
dc.subject.otherSurvival
dc.subject.otherPeritoneal Diseases
dc.subject.otherCytoreduction Surgical Procedures
dc.subject.otherHyperthermic Intraperitoneal Chemotherapy
dc.titleAssessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
dc.title.alternativeAvaliação da morbimortalidade e da sobrevida em pacientes portadores de carcinomatose peritoneal submetidos a cirurgia citorretorredutora e quimioterapia hipertérmica intraperitoneal (HIPEC)
dc.typeArtigo de periódico
local.citation.epage11
local.citation.issuee20233421
local.citation.spage1
local.citation.volume50
local.description.resumoPeritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma, or secondary PC, such as colorectal cancer (CRC) or pseudomixoma. Until recently, such patients were deemed untreatable. Objective: The purpose of this study was to assess the results of CRS + HIPEC in patients with PC. Postoperative complications, mortality and survival rates were evaluated according to the diagnosis. Results: Fifty-six patients with PC, undergoing full CRS + HIPEC between October 2004 and January 2020, were enrolled. The mortality rate was 3.8% and the morbidity rate was 61.5%. Complications were significantly higher in proportion to the duration of surgery (p<0.001). The overall survival rates, as shown in the Kaplan-Meyer curve, were respectively 81%, 74% and 53% at 12, 24 and 60 months. Survival rates according to each diagnosis for the same periods were 87%, 82% and 47% in patients with pseudomixoma, and 77%, 72% and 57% in patients with CRC (log-rank 0.371, p=0.543). Conclusion: CRS with HIPEC is an option for pacients with primary or secondary PC. Although complication rates are high, a longer survival rate may be attained compared to those seen in previously published results; in some cases, patients may even be cured.
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE CIRURGIA
local.publisher.initialsUFMG
local.url.externahttps://doi.org/10.1590/0100-6991e-20233421-en

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Assessing morbidity, mortality pdfa.pdf
Tamanho:
455.95 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG